Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

about

The Identification of Immunological Biomarkers in Kidney Cancers

P2860

Q59132089-588788AD-A214-4983-B660-68BD7D40B895

P2860

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

Item

http://www.wikidata.org/entity/Q55101776

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

@en

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

@nl

type

Item

label

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

@en

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

@nl

prefLabel

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

@en

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

@nl

P1476

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications

@en

P2093

Antonio Lopez-Beltran

http://www.w3.org/2001/XMLSchema#string

Liang Cheng

http://www.w3.org/2001/XMLSchema#string

Marina Scarpelli

http://www.w3.org/2001/XMLSchema#string

Matteo Santoni

http://www.w3.org/2001/XMLSchema#string

Nicola Battelli

http://www.w3.org/2001/XMLSchema#string

Rodolfo Montironi

http://www.w3.org/2001/XMLSchema#string

P2860

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.

Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

P304

212528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.7573/DIC.212528

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29899754

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5992965

http://www.w3.org/2001/XMLSchema#string

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

about

P2860

P2860

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932